|Day Low/High||62.06 / 62.58|
|52 Wk Low/High||43.83 / 64.60|
- XIENCE Sierra™, the newest generation of XIENCE drug-eluting stents, received U.S. Food and Drug Administration (FDA) approval
- Promising results for Tendyne valve presented as late-breaking clinical trial at EuroPCR
Conference highlights from Honeywell bolster the investment case.
- Late-breaking data presented at EuroPCR and simultaneously published in "The New England Journal of Medicine" support use of Abbott's PressureWire™ guidewire to help physicians make stenting decisions
Jim discusses Macy's quarter as a readthrough to Nordstrom, defense and North Korea, and more on the market!
President Trump reduced tensions in Korea, raised them in the Middle East, and mainly relieved them for investors in the drug and healthcare industries.
The markets strongly rebounded this week as a few of the major averages pushed into positive year-to-date territory.
- ADVISOR™ HD GRID MAPPING CATHETER, SENSOR ENABLED™ FACILITATES IMPROVED DATA COLLECTION, SUPPORTING OPTIMAL TREATMENT FOR PATIENTS WITH COMPLEX CARDIAC ARRHYTHMIAS
- Provides patients with access to latest-generation gold-standard heart stent through Japan's health insurance system
On a rough day for markets we review new additions to our investing bullpen.
LONG-TERM AGREEMENT BETWEEN SANQUIN, A LEADER IN BLOOD SERVICES, AND ABBOTT, A GLOBAL LEADER IN TRANSFUSION MEDICINE, HELPS ENSURE A SAFE AND EFFICIENT BLOOD SUPPLY IN THE NETHERLANDS
Stocks finish mixed on Wednesday amid a sharp decline in IBM shares.
Jim Cramer and our other experts look at banks, three sections to trade, and REITs.
FreeStyle Libre already has over 50,000 users in the U.S. since being approved for sale in the U.S. last September.
Abbott sees full year earnings of between $2.80 to $2.90 a share after a solid first quarter that topped Wall Street forecasts.
Market reactions have ranged anywhere from lackluster to outright negative. What gives?
U.S. stock futures rise modestly; IBM tumbles after it reports a weaker-than-expected profit margin; the NTSB says the blown engine on a Southwest plane had 'metal fatigue.'
Abbott's Freestyle Libre in September secured FDA approval and in January, the company said the device had received reimbursement from the Centers for Medicare & Medicaid Services.
Jim Cramer highlights Spotify, Alkermes, Sorrento Therapeutics, Thermo Fisher Scientific, Kohlberg Kravis Roberts, and more.
Not every battle is worth fighting, says Jim Cramer. That's especially true if you own shares of Newell Brands.
Curtis Morgan, president and CEO of Vistra Energy, talks to Jim Cramer about the outlook for coal and renewables.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.